TABLE 3.
Neuropathological evaluation of monkeys inoculated i.c. with ChimeriVax-JE FRhL3 FRhL5 or YF 17D (YF-VAX) and necropsied on day 30 postinoculation
| Test virus | Monkey | Sex | Dosea (log10 PFU/ 0.25 ml) | Clinical scoreb maximum score/ mean daily score | Individual and group mean histopathological score
|
||
|---|---|---|---|---|---|---|---|
| Target areac | Discriminactor areasd | Target plus discrim- inator areas | |||||
| YF-VAX (Connaught lot no. 0986400) | RT702M | M | 4.05 | 1/0 | 2.00 | 0.51 | 1.26 |
| RT758M | M | 4.28 | 1/0 | 0.25 | 0.01 | 0.13 | |
| RT653M | M | 4.07 | 1/0 | 2.00 | 0.39 | 1.20 | |
| RT776M | M | 4.25 | 3/1 | 2.00 | 1.29 | 1.65 | |
| RT621M | M | 4.34 | 3/2 | 1.00 | 0.46 | 0.73 | |
| RAH80F | F | 4.14 | 3/1 | 1.50 | 0.71 | 1.10 | |
| RAL02F | F | 4.13 | 1/1 | 2.00 | 0.80 | 1.40 | |
| RT698F | F | 3.78 | 3/1 | 1.50 | 0.64 | 1.07 | |
| RAI12F | F | 4.11 | 1/1 | 2.00 | 1.45 | 1.73 | |
| RP942F | F | 4.05 | 1/0 | 2.00 | 0.81 | 1.41 | |
| Mean | 4.12 | 1 | 1.63 | 0.71 | 1.17 | ||
| SD | 0.16 | 1 | 0.59 | 0.42 | 0.47 | ||
| ChimeriVax-JE, FRhL3 (lot no. 1031299A) | RT452M | M | 3.55 | 1/0 | 0.50 | 0.08 | 0.29 |
| RR257M | M | 3.52 | 1/0 | 1.00 | 0.14 | 0.57 | |
| RT834M | M | 3.71 | 1/0 | 0.50 | 0.38 | 0.44 | |
| RT620M | M | 3.71 | 1/0 | 1.00 | 0.14 | 0.57 | |
| RT288M | M | 3.76 | 1/0 | 0.50 | 0.19 | 0.35 | |
| RAJ98F | F | 3.79 | 1/1 | 0.00 | 0.11 | 0.05 | |
| RAR08F | F | 3.52 | 1/0 | 0.00 | 0.13 | 0.07 | |
| RV481F | F | 3.52 | 1/0 | 0.00 | 0.06 | 0.03 | |
| RT841F | F | 3.71 | 1/0 | 0.50 | 0.05 | 0.28 | |
| RT392F | F | 3.76 | 1/0 | 0.50 | 0.07 | 0.29 | |
| Mean | 3.66 | 0 | 0.45 | 0.14 | 0.29 | ||
| SD | 0.11 | 0 | 0.37 | 0.10 | 0.20 | ||
| P value (t teste) vs YF-VAX | 0.037/0.025 | 0.00008 | 0.00191 | 0.00014 | |||
| ChimeriVax JE, FRhL5 (lot no. 99B01) | RT628M | M | 4.20 | 1/0 | 0.50 | 0.57 | 0.54 |
| RT678M | M | 4.19 | 1/0 | 1.00 | 0.12 | 0.60 | |
| RT581M | M | 4.17 | 1/0 | 1.00 | 0.46 | 0.73 | |
| RR726M | M | 4.32 | 1/0 | 1.00 | 0.66 | 0.83 | |
| RR725M | M | NDf | 1/0 | 1.00 | 0.33 | 0.67 | |
| RAJ55F | F | 4.27 | 0/0 | 1.00 | 0.14 | 0.57 | |
| RT769F | F | 4.44 | 1/0 | 1.00 | 0.58 | 0.79 | |
| RAK22F | F | 4.24 | 1/0 | 0.00 | 0.12 | 0.06 | |
| RT207F | F | 4.49 | 1/1 | 1.00 | 0.22 | 0.61 | |
| RT490F | F | 4.34 | 1/0 | 0.00 | 0.04 | 0.02 | |
| Mean | 4.30 | 0 | 0.75 | 0.32 | 0.54 | ||
| SD | 0.11 | 0 | 0.42 | 0.23 | 0.28 | ||
| P value (t test) vs YF-VAX | 0.024/0.025 | 0.00154 | 0.02436 | 0.00248 | |||
| P value (t test) vs ChimeriVax-JE, FRhL3 | 0.343/1.00 | 0.10942 | 0.03223 | 0.03656 | |||
Back titration.
Clinical score: 0, no signs; 1, rough coat, not eating; 2, high-pitched voice, inactive, slow moving; 3, tremor, incoordination, shaky movements, limb weakness; 4, inability to stand, paralysis, moribund, or dead. The maximum score on any day and the mean score over the 30-day observation period are shown.
Substantia nigra.
Corpus striatum and thalamus, right and left side (caudate nucleus, globus pallidus, putamen, anterior/medial thalamic nucleus, lateral thalamic nucleus, and cervical and lumbar enlargements of the spinal cord [six levels]).
Student's t test (two sided, heteroscedastic), comparing YF-VAX and ChimeriVax-JE viruses.
ND, not done.